Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 24 February 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Cancer incidence and mortality with long-segment Barrett's Esophagus

The annual risk of developing high-grade dysplasia or adenocarcinoma in patients with long-segment BE is 0.83%, however, death due to adenocarcinoma is uncommon, even in patients with long-segment BE, reports December's issue of the Scandinavian Journal of Gastroenterology.

News image

fiogf49gjkf04

Data on cancer risk in patients with long-segment Barrett's esophagus (BE) from older studies are often difficult to interpret, since the definition of BE has evolved from an endoscopical to a histological diagnosis.

In this work, Dr Hage and colleagues from The Netherlands, the diagnoses in the Rotterdam BE cohort on current standards was redefined to obtain more accurate data on cancer risk in patients who had not undergone standard endoscopic surveillance.

In addition, the researcgers determined which patient factors present at index endoscopy were associated with neoplastic progression in BE.

The Rotterdam BE cohort analyzed by the research team, comprises all patients with ≥3 cm BE, diagnosed at endoscopy between 1973 and 1984.

The researchers only included patients with intestinal metaplasia in this study, totaling 105 participants.

The research team obtained follow-up data by questionnaires and/or interviews with patients or treating physicians. They then used a Kaplan-Meier analysis to estimate 20-year risks.

1 cancer case per 221 patient-years and 1 case of high-grade dysplasia per 266 patient-years
Scandinavian Journal of Gastroenterology

The researchers found that the mean length of the BE was 7.1 cm (range: 3-15 m).

In addition, the researchers noted that cancer in BE developed in 6% of patients, and high-grade dysplasia (HGD) in 5% during 1329 patient-years of follow-up.

This equates to 1 cancer case per 221 patient-years and 1 HGD case per 266 patient-years.

The research team recorded 72 deaths (69% of patients) after a mean follow-up of 12.7 years; only 4 of them died of esophageal cancer or its treatment.

The researchers found that a longer length of BE was associated with an increased risk of progression to HGD or cancer.

6 of 24 patients who never had low-grade dysplasia progressed to HGD or cancer 2-16 years after a diagnosis of BE.

Dr Hage concluded, "The annual risk of developing HGD or adenocarcinoma in patients with long-segment BE is 0.83%."

"Death due to adenocarcinoma is, however, uncommon, even in a cohort of patients with long-segment BE."

Scandinavian Journal of Gastroenterology; 2004: 39 (12): 1175 - 1179
23 November 2004

Go to top of page Email this page Email this page to a colleague

 23 February 2018 
Patients on antithrombotic agents undergoing emergency and elective endoscopy
 23 February 2018 
Heavy metals on a gluten-free diet
 23 February 2018 
MRI and NAFLD
 22 February 2018 
Outcomes with Crohn’s after infliximab withdrawal
 22 February 2018 
Elderly onset of IBD

 22 February 2018 
Autophagy enhancers
 21 February 2018 
Management of hemorrhoids in the USA
 21 February 2018 
Adalimumab and infliximab in biologic-naïve Crohn's
 21 February 2018 
Cystic fibrosis and colorectal cancer
 20 February 2018 
Complications and surveillance colonoscopies
 20 February 2018 
Treatment algorithm for polyp cancers
 20 February 2018 
Predictors of postoperative infection in Crohn's
 19 February 2018 
Screening colonoscopy in the right and left colon
 19 February 2018 
NAFLD prevalence in the USA
 19 February 2018 
Fructans in children with IBS

 16 February 2018 
Inflammatory bowel diseases are global diseases
 16 February 2018 
Undetected celiac in the elderly
 16 February 2018 
Fructans induce non-celiac gluten sensitivity
 15 February 2018 
NSAIDS and GI damage
 15 February 2018 
Oral direct-acting antiviral treatment for Hep C virus genotype 1
 15 February 2018 
Primary vs secondary surgery for the presence of lymph node metastasis
 14 February 2018 
Predicting adenoma detection rate
 14 February 2018 
Normal bowel frequency characterization in the USA 
 13 February 2018 
Personalising treatment options for IBS
 13 February 2018 
Prebiotics improve endothelial dysfunction
 13 February 2018 
Diagnostic criteria for a Rome IV functional gastrointestinal disorders
 12 February 2018 
Visceral hypersensitivity and functional GI disorders
 12 February 2018 
Depression and aggressive IBD
 12 February 2018 
Variability in interpretation of endoscopic findings impacts patient management
 09 February 2018 
Treatment of choice for anastomotic stricture in IBD
 09 February 2018 
PRO measurement information system 
 09 February 2018 
Overall disease severity indices for IBD
 08 February 2018 
Prediction of endoscopically active disease

 08 February 2018 
Steroid-refractory acute severe ulcerative colitis
 08 February 2018 
Decision aid used by IBD patients
 07 February 2018 
Ursodeoxycholic acid combined with bezafibrate for itching
 07 February 2018 
Change in microbiome in gastritis vs gastric carcinoma
 07 February 2018 
Colorectal cancer and primary sclerosing cholangitis-IBD
 06 February 2018 
Risk of death after liver transplantation
 06 February 2018 
Crohn’s disease vs refractory pouchitis
 06 February 2018 
Support for functional dyspepsia symptom diary
 05 February 2018 
Helicobacter spp influence on GI tract 
 05 February 2018 
No link found between severe reflux and all-cause mortality 
 05 February 2018 
Psychological distress in PPI non-responders
 02 February 2018 
Assessing psychosexual impact of IBD
 02 February 2018 
Decrease in overall mortality with cholera vaccination
 02 February 2018 
Diagnostic performance of fecal immunochemical tests
 01 February 2018 
Screening frequency with family histories of colorectal cancer
 01 February 2018 
IBD and sport participation
 01 February 2018 
Life with a stoma 
 31 January 2018 
Aprepitant and gastroparesis 
 31 January 2018 
Anesthesia risk in colonoscopy
 31 January 2018 
GED-0301 for Crohn's Disease
 30 January 2018 
Intestinal dysbiosis and allergic diseases in infants
 30 January 2018 
Fructans and IBS symptoms in children
 29 January 2018 
Dosing calculator for therapy optimization in IBD
 29 January 2018 
Glecaprevir–pibrentasvir for in HCV
 29 January 2018 
Food allergen injections in eosinophilic esophagitis
 29 January 2018 
Reliability of the IBD index
 26 January 2018 
Tofacitinib vs biological therapies for ulcerative colitis

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us